The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

TMS and Exercise for Post-stroke Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04672044
Recruitment Status : Recruiting
First Posted : December 17, 2020
Last Update Posted : December 12, 2023
Sponsor:
Information provided by (Responsible Party):
VA Office of Research and Development

Tracking Information
First Submitted Date  ICMJE December 11, 2020
First Posted Date  ICMJE December 17, 2020
Last Update Posted Date December 12, 2023
Actual Study Start Date  ICMJE January 14, 2022
Estimated Primary Completion Date June 30, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 11, 2020)
Visual Analogue Scale for Pain [ Time Frame: through study completion, an average of 12 weeks ]
The visual analog scale (VAS) is a validated, subjective measure for pain. Scores are based on self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale-"no pain" on the left end (0 cm) of the scale and the "worst pain" on the right end of the scale (10 cm)
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures
 (submitted: December 11, 2020)
modified Rankin Scale [ Time Frame: through study completion, an average of 12 weeks ]
Measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Score Description: 0 No symptoms at all
  1. No significant disability despite symptoms; able to carry out all usual duties and activities
  2. Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance
  3. Moderate disability; requiring some help, but able to walk without assistance
  4. Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance
  5. Severe disability; bedridden, incontinent and requiring constant nursing care and attention
  6. Dead
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE TMS and Exercise for Post-stroke Pain
Official Title  ICMJE Feasibility of Combination Exercise and Neuromodulation Rehabilitation to Improve Post-stroke Chronic Pain
Brief Summary There are over 7 million people living with stroke in the United States. Per year, approximately 17,000 Veterans are admitted to the VA for acute stroke. Chronic pain after stroke can occur between 10-50% of stroke survivors. Post-stroke pain (PSP) can lead to further complications in a stroke survivor's recovery. Exercise has improved PSP and associated symptoms such as mobility, fatigue, and quality of life. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive technique using electromagnetic induction for cortical neurostimulation. The use of rTMS has been explored shown to be effective in treating chronic PSP but is limited in effect duration. Our proposal will test the hypothesis that rTMS is feasible and safe to be paired with exercise. Additionally, the investigators believe a complementary effect can develop to enhance the neurostimulation duration of rTMS.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Feasibility of a double-blind sham-controlled intervention
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Double-blind
Primary Purpose: Treatment
Condition  ICMJE Chronic Post-stroke Headache
Intervention  ICMJE
  • Device: Active rTMS and exercise
    active
  • Combination Product: Sham rTMS+Exercise
    sham
Study Arms  ICMJE
  • Active Comparator: active rTMS+Exercise
    active rTMS
    Intervention: Device: Active rTMS and exercise
  • Sham Comparator: sham rTMS+Exercise
    sham rTMS
    Intervention: Combination Product: Sham rTMS+Exercise
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: December 11, 2020)
32
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 30, 2024
Estimated Primary Completion Date June 30, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female Veteran of US military 19 years of age
  • Signed informed consent
  • Minimum of 3-months since time of stroke and medically stable
  • Headache has persisted for >3 months after stabilization of the stroke
  • Ability to walk or tolerate recumbent cycle ergometry for 10 mins without assistance
  • Stable pain medication regimen for 1 month prior to study
  • Females of child-bearing potential (i.e. not postmenopausal or surgically sterile) must be using a medically acceptable method of birth control and should not be pregnant nor have plans for pregnancy or breastfeeding during the study
  • Completed diagnostic, maximal graded exercise test including 12-lead ECG and indirect calorimetry (i.e. oxygen uptake, minute ventilation, respiratory exchange ratio, etc.)
  • Minimum pain intensity of 30 on the Mechanical Visual Analogue Scale on average with pain symptoms.

Exclusion Criteria:

  • Moderate to severe cognitive impairment (Montreal Cognitive Assessment score <16/30)
  • Pre-stroke modified Rankin >2
  • History of seizures
  • Presence of any standard TMS or MRI contraindications (see human subjects)
  • Current diagnosis of DSM-5-defined bipolar disorder I, schizophrenia, schizoaffective disorder, or obsessive-compulsive disorder
  • Diagnosis of moderate or severe substance use disorder (except for caffeine and nicotine) during the preceding 3 months (Participants must agree to abstain from illicit drugs during the study)
  • Increased risk of suicide that necessitates inpatient treatment or warrants additional therapy excluded by the protocol; and/or intensity of suicidal ideation (Type 4 or Type 5) or any suicidal behavior in the past 3 months on Columbia Suicide Severity Rating Scale (C-SSRS)
  • Litigating for compensation for a psychiatric disorder

    • Veterans who are in the process of applying for or receiving VA service-connected disability are eligible
  • Current enrollment in another intervention trial for pain or stroke
  • Persons imprisoned, of minor age, diagnosed with terminal illness, or require surrogate for consent
  • Fails baseline exercise screening activities
  • Persistent post-stroke headaches not better accounted for by another diagnosis
  • Is unable to reliably attend intervention sessions i.e. planning to move, transportation issues
  • Neurological disorder pre- or post- stroke affecting subject's ability to follow study directions
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 19 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Chen Lin, MD (205) 933-8101 Chen.Lin@va.gov
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04672044
Other Study ID Numbers  ICMJE B3612-P
I21RX003612 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party VA Office of Research and Development
Original Responsible Party Same as current
Current Study Sponsor  ICMJE VA Office of Research and Development
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Chen Lin, MD Birmingham VA Medical Center, Birmingham, AL
PRS Account VA Office of Research and Development
Verification Date December 2023

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP